BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
97.8%+6.5 pts over 5 years
Operating margin
39.0%+1020.1 pts over 5 years
Net margin
30.2%+1056.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +94.1% | +47.8% | +117.9% | +33.6% | |
| Gross profit | +95.2% | +47.9% | +120.9% | +33.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -223.7% | -1925.4% | -88.7% | |
| Return on assets | -52.0% | -71.7% | 52.5% | |
| Current ratio | 1.23 | 3.06 | 2.06 | |
| Debt to equity | – | -6.22 | 0.00 | |
| Net debt to EBITDA | – | 0.88× | -0.26× | |
| Interest coverage | -7.5× | -12.1× | 4.3× | |
| Inventory turnover | 2.2× | 0.4× | 2.8× | |
| Capex to revenue | 20.0% | 2.9% | 0.3% | |
| Diluted shares | 74M | 167M | 219M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biocryst Pharmaceuticals generated $798.54M from operations and spent $9.50M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$798.54M
Used
$9.50M
Capital expenditure$9.50M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin30.2%
×Asset turnover1.74×
×Equity multiplier-1.69×
=Return on equity, FY2025-88.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 30.2% | 1.74× | -1.69× | -88.7% |
| FY2024 | -19.7% | 0.89× | -1.08× | 19.1% |
| FY2023 | -68.4% | 0.62× | -1.42× | 60.4% |
| FY2022 | -91.2% | 0.48× | -2.83× | 123.1% |
| FY2021 | -117.1% | 0.34× | -7.31× | 291.6% |
| FY2020 | -1026.4% | 0.07× | 26.86× | -1925.4% |
| FY2019 | -223.0% | 0.30× | 3.68× | -248.9% |
| FY2018 | -490.3% | 0.13× | 2.44× | -152.3% |
| FY2017 | -261.2% | 0.19× | 3.14× | -154.2% |
| FY2016 | -209.3% | 0.25× | 4.30× | -223.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$263.86M
- Cash generatingOperating cash flow above zero$347.37M
- Return on assets improvedROA up on the prior year-17.2% → 53.8%
- Earnings backed by cashOperating cash flow above net income$347.37M vs $263.86M
- Less leverageLong-term debt to assets fell64.2% → 0.0%
- Better liquidityCurrent ratio rose2.63 → 2.06
- No dilutionShare count did not rise207M → 219M
- Gross margin improvedGross margin up on the prior year97.28% → 97.82%
- More efficientAsset turnover rose0.87 → 1.78